U.S. markets open in 6 hours 20 minutes
  • S&P Futures

    4,240.75
    +9.25 (+0.22%)
     
  • Dow Futures

    33,852.00
    +93.00 (+0.28%)
     
  • Nasdaq Futures

    14,296.75
    +33.75 (+0.24%)
     
  • Russell 2000 Futures

    2,307.30
    +7.00 (+0.30%)
     
  • Crude Oil

    73.41
    +0.33 (+0.45%)
     
  • Gold

    1,776.50
    -6.90 (-0.39%)
     
  • Silver

    25.94
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1942
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    16.32
    -0.34 (-2.04%)
     
  • GBP/USD

    1.3968
    +0.0005 (+0.03%)
     
  • USD/JPY

    110.8670
    -0.0950 (-0.09%)
     
  • BTC-USD

    32,964.41
    -980.54 (-2.89%)
     
  • CMC Crypto 200

    796.89
    -13.30 (-1.64%)
     
  • FTSE 100

    7,074.06
    0.00 (0.00%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.

Mr. Lucchino’s presentation will take place on Wednesday, April 14 at 8:00 a.m. EDT.

A live webcast of the presentation can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of the presentation will be posted on the Frequency website following the event.

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.

Headquartered in Woburn, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005033/en/

Contacts

Investor Contact:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
617-914-0008

Media Contact:
Suzanne Day
Frequency Therapeutics
sday@frequencytx.com
781-496-2211